Hepatic senescence, the good and the bad
Nazmul Huda1, Gang Liu1, Honghai Hong1
1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
World Journal of Gastroenterology
|September 28, 2019
Summary
Cellular senescence, a state of irreversible cell cycle arrest, contributes to aging and liver diseases. Understanding senescence mechanisms is key to addressing liver health and age-related conditions.
Area of Science:
- Cell Biology
- Gastroenterology
- Gerontology
Background:
- Cellular senescence is a state of permanent cell cycle arrest with metabolic activity.
- Senescence is characterized by multiple markers, not a single one.
- Senescence-associated secretory phenotype (SASP) impacts tissue microenvironments.
Purpose of the Study:
- To review molecular mechanisms of cellular senescence.
- To explore the relationship between senescence and liver diseases.
- To understand senescence's role in liver aging and disease etiology.
Main Methods:
- Literature review of recent findings on cellular senescence.
- Analysis of molecular mechanisms driving senescence.
- Examination of senescence markers and SASP in liver tissue.
Main Results:
- Senescence contributes to age-related decline in liver function and regeneration.
- Hepatocytes and cholangiocytes are key drivers of liver senescence.
- Senescent cells are implicated in chronic liver diseases like cirrhosis and hepatocellular carcinoma.
Conclusions:
- Cellular senescence plays a significant role in liver aging and disease.
- Further research into senescence mechanisms can inform therapeutic strategies for liver conditions.
- Targeting senescence may offer new avenues for treating age-related liver pathologies.
Keywords:
Cell cycle arrestCholangiocyteDNA damageHepatic stellate cellHepatocyteSenescenceSenescence associated secretory phenotypeMore Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
217
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
198
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
198
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
216
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
216
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
01:22Bioavailability: Influencing Factors
345
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
345